Advertisement

Controversial Aspects of Hormone Manipulation in Prostatic Carcinoma

  • J. Altwein
Part of the NATO Advanced Science Institutes Series book series (NSSA, volume 53)

Abstract

The biochemical similarity between the patient’s normal and his cancerous prostatic tissue is one essential prerequisite for successful hormone manipulation basically directed at the deprivation of androgenic influences upon the prostate. In achieving this goal every therapeutic modality still relies on classical androgen control principles; however, new developments in the field of chemotherapeutic drugs and antihormones are being tested in multicenter phase II and III trials, e.g. under the auspices of the National Prostatic Cancer Project and the EORTC.

Keywords

Prostatic Carcinoma Medroxyprogesterone Acetate Ureteral Obstruction Intrahepatic Cholestasis Cyproterone Acetate 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    P.C. Walsh, Physiologic Basis for Hormonal Therapy in Carcinoma of the Prostate, Urol. Clin. N Amer. 2:125 (1975).Google Scholar
  2. 2.
    C.E. Carlton, Combined Interstitial and External Radiotherapy in the Definitive Management of Carcinoma of the Prostate, Presented at The International Symposium on the Treatment of Carcinoma of the Prostate, Berlin, (1978).Google Scholar
  3. 3.
    S. Michigan and W.J. Catalona, Ureteral Obstruction from Prostatic Carcinoma: Response to Endocrine and Radiation Therapy, J. Urol. 118:733 (1977).PubMedGoogle Scholar
  4. 4.
    H. Gottinger and E. Schmiedt, Therapie des Prostatakarzinoms, Fortschr Med. 97:1881 (1979).PubMedGoogle Scholar
  5. 5.
    R. Hartung and W. Mauermayer, Therapie und Nachsorge des Prostatakarzinoms, Ther Gegenwart 118:162 (1979).PubMedGoogle Scholar
  6. 6.
    G. Birke and L. Waldstrom, Progynon, A Depot Preparation with Oestrogenic Action in the Treatment of Prostate Carcinoma. Acta Chir. Scand 130:388 (1965).PubMedGoogle Scholar
  7. 7.
    R.M. Anikwe, Effect of Estrogen Therapy on Metastatic Carcinoma of the Prostate, Int. Surg 62:532 (1977).PubMedGoogle Scholar
  8. 8.
    W.S. Falkowski and V.J. O’Conor Jr, Long-term Survivor of Prostatic Carcinoma with Lung Metastases, J. Urol. 125:260 (1981).PubMedGoogle Scholar
  9. 9.
    R. De Vere White, D.F. Paulson and J.D. Glenn, The Clinical Spectrum of Prostatic Cancer, J. Urol. 117:23 (1977).Google Scholar
  10. 10.
    M. Menon and P.C. Walsh, Hormonal Therapy for Prostatic Cancer in “Prostatic Cancer”, G.P. Murphy (ed), PSG Publishing Company, Littleton (1979) p. 175.Google Scholar
  11. 11.
    D.P. Byar, The Veterans Administration Cooperative Urological Research Group’s Studies of Cancer of the Prostate, Cancer 32:1126 (1973).PubMedCrossRefGoogle Scholar
  12. 12.
    W.P. Jordan, C.E. Blackard and D.P. Byar, Reconsideration of Orchiectomy in the Treatment of Advanced Prostatic Carcinoma, South.Med. J. 70:1411 (1977).PubMedGoogle Scholar
  13. 13.
    D.F. Paulson, The Role of Endocrine Therapy in the Management of Prostatic Cancer, in “Genitourinary Cancer”, D.G. Skinner and J.D. deKernion (eds), W.B. Saunders Company, Philadelphia, London and Toronto, (1978) p. 388.Google Scholar
  14. 14.
    J.L. Emmett, L.F. Greene and A. Papantoniou, Endocrine Therapy in Carcinoma of the Prostate Gland: 10-year Survival Studies, J. Urol. 83:471 (1960).PubMedGoogle Scholar
  15. 15.
    K. Ochiai and H. Takeuchi, Some Consideration on Rational for an Antiandrogenic Treatment of Advanced Prostatic Carcinoma, in “Proceedings of the 16th Congress of the International Society of Urology, Doin, Paris (1973) p. 256.Google Scholar
  16. 16.
    H. Brendler and G. Prout, A Cooperative Group Study of Prostatic Cancer: Stilbestrol Versus Placebo in Advanced Progressive Disease, Cancer Chemother. Rep. 16:323 (1962).PubMedGoogle Scholar
  17. 17.
    M. Kontturri and E. Sotaniemi, Effect of Estrogen on Liver Function of Prostatic Cancer Patients, Brit. Med. J. i:204 (1969)CrossRefGoogle Scholar
  18. 18.
    U. Kunze and F. Orestano, Intra-und Extrazellulare Elektrolytkonzentration Unter Oestrogen-Therapie bei Prostatacarcinompat-ienten, Urologa A 12:274 (1973).Google Scholar
  19. 19.
    J. Geller, B. Fruchtman, H. Newman, T. Roberts and R. Silva, Effect of Progestational Agents on Carcinoma of the Prostate, Cancer Chemother. Rep. 51:41 (1967).PubMedGoogle Scholar
  20. 20.
    S. Rafla and R. Johnson, The Treatment of Advanced Prostatic Carcinoma with Medroxyprogesterone, Curr. Ther. Res. 16:261 (1974).PubMedGoogle Scholar
  21. 21.
    F. Pannuti, A.P. Rossi and E. Piana, Massive Doses of Medroxyprogesterone Acetate (MPA): Pilot Study in the Treatment of Advanced Prostate Cancer, IRCS Med. Sci. 5:375 (1977).Google Scholar
  22. 22.
    O.M. Cramer, C.R. Parker and J.C. Porter, Stimulation of Dopamine Release into Hypophyseal Portal Blood by Administration of Progesterone, Endocrinol. 105:929 (1979).CrossRefGoogle Scholar
  23. 23.
    C.H. Bouffioux, Le Cancer de la Prostate, Acta Urol Belg 47:189 (1979).PubMedGoogle Scholar
  24. 24.
    S. Sander, R. Nissen-Meyer and A. Aakvaag, On Gestagen Treatment of Advanced Prostatic Carcinoma, Scand J Urol. Nephrol. 12:119 (1978).PubMedCrossRefGoogle Scholar
  25. 25.
    D.P. Byar, VACURG Studies on Prostatic Cancer and Its Treatment, in “Urologic Pathology: The Prostate”, M. Tannenbaum (ed), Lea & Febiger, Philadelphia (1977) p. 241.Google Scholar
  26. 26.
    M. Pavone-Macaluso, Phase III Studies of the EORTC: Treatment of Prostatic Carcinoma with Antihormones, Presented at Anti-hormones — Current Knowledge and Prospective Clinical Relevance in Urology, Innsbruck (1979).Google Scholar
  27. 27.
    C.H. Bouffioux, Treatment of Prostatic Cancer with Medroxypro-gesterone-acetate (MPA), in “Bladder Tumors and Other Topics in Urological Oncology, M. Pavone-Macaluso, P.H. Smith and F. Edsmyr (eds), Plenum Publishing Corporation, New York (1980), p. 463.CrossRefGoogle Scholar
  28. 28.
    A. Kocze and J. Szekely, Tamoxifen in Advanced Prostatic Carcinoma, Lancet i:539 (1980).CrossRefGoogle Scholar
  29. 29.
    M Osama El-Arimi, Response to Tamoxifen in Drug-Reistant Prostatic Carcinoma, Lancet ii:588 (1979).CrossRefGoogle Scholar
  30. 30.
    J. Geller, J. Albert and S.S.C. Yen, Treatment of Advanced Cancer of the Prostate with Megestrol Acetate, Urology 12:537 (1978).PubMedCrossRefGoogle Scholar
  31. 31.
    G.R. Prout, R.J. Irwin, B. Kliman, J.J. Daly, R.A. McLaughlin and P.P. Griffin, Prostatic Cancer and Sch 13521: II. Histological Alterations and the Pituitary Gonadal Axis, J. Urol. 113:834 (1975).PubMedGoogle Scholar
  32. 32.
    P.C. Sogani and W.F. Whitmore, Experience with Flutamide in Previously Untreated Patients with Advanced Prostatic Cancer, J. Urol. 122:640 (1979).PubMedGoogle Scholar
  33. 33.
    R.A. Airhart, T.F. Barnett, J.W. Sullivan, R.L. Levine and J.U. Schlegel, Flutamide Therapy for Carcinoma of the Prostate, South Med. J. 71:798 (1978).PubMedCrossRefGoogle Scholar
  34. 34.
    E. Jacobo, J. Schmidt, S. Weinstein and R. Flocks, Comparison of Flutamide (Schr 13521) and Diethylstilbestrol in Untreated Advanced Prostatic Cancer, Urology 8:231 (1976).PubMedCrossRefGoogle Scholar
  35. 35.
    D.K. Fukushima, J. Levin, J. Kream, S.Z. Freed, W.F. Whitmore, L. Hellman and B. Zumoff, Effect of Flutamide on Cortisol Metabolism. J. Clin. Endocrinol. Metab. 47:788 (1978).PubMedCrossRefGoogle Scholar
  36. 36.
    B. Zumoff, J. Fishman, S. Freed, J. Levin, W.F. Whitmore Jr, L. Hellman and D.K. Fukushima, Effect of Flutamide on Estradiol Metabolism, J. Clin. Endocrinol. Metab. 49:467 (1979).PubMedCrossRefGoogle Scholar
  37. 37.
    U. Bracci, Antiandrogens in the Treatment of Prostatic Cancer, Eur. Urol. 5:303 (1979).PubMedGoogle Scholar
  38. 38.
    G.H. Jacobi, J.E. Altwein, K.H. Kurth, R. Basting and R. Hohenfellner, Treatment of Advanced Prostatic Cancer with Parenteral Cyproterone Acetate: A Phase III Randomised Trial, Brit. J. Urol. 52:208 (1980).PubMedCrossRefGoogle Scholar
  39. 39.
    W.W. Scott and H.K.A. Schirmer, A New Progestational Steroid Effective in the Treatment of Prostatic Cancer, Trans Amer Assoc. GU Surg. 58:54 (1966).Google Scholar
  40. 40.
    A.J. Wein and J.J. Murphy, Experience in the Treatment of Prostatic Carcinoma with Cyproterone Acetate, J. Urol. 109:68 (1973).PubMedGoogle Scholar
  41. 41.
    J. Geller, G. Vazakas, B. Fruchtman, H. Newman, K. Nakao and A. Loh, The Effect of Cyproterone Acetate on Advanced Carcinoma of the Prostate, Surg. Gyn. Obst. 127:748 (1968).PubMedGoogle Scholar
  42. 42.
    A.R. Stone, T.B. Hargreave and G.D. Chisholm, The Diagnosis of Estrogen Escape and the Role of Secondary Orchiectomy in Prostatic Cancer, Brit. J. Urol. 52:535 (1980).PubMedCrossRefGoogle Scholar
  43. 43.
    G.L. Biorn, C.P. Gray and E. Strauss, Orchiectomy After Presumed Estrogen Failure in Treatment of Carcinoma of the Prostate, West J. Med. 130:363 (1979).PubMedGoogle Scholar
  44. 44.
    L. Denis and P. Nowe, Bilateral Orchiectomy in Patients with Progressive Advanced Prostatic Cancer, Acta Urol. Belg 48:113 (1980).PubMedGoogle Scholar
  45. 45.
    C.E. Merrin, Treatment of Previously Untreated (By Hormonal Manipulation) Stage D Adenocarcinoma of Prostate with Combined Orchiectomy, Estrogens and Cisdiamminedichloro-platinum, Urology 15:123 (1980).PubMedCrossRefGoogle Scholar
  46. 46.
    A.H. Bennett, J.B. Dowd and J.H. Harrison, Estrogen and Survival Data in Carcinoma of the Prostate, Surg. Gyn. Obst. 129:505 (1972)Google Scholar
  47. 47.
    G.P. Murphy, Current Status of Therapy in Prostatic Cancer, in “Urologic Pathology: The Prostate”, M. Tannenbaum (ed), Lea & Febiger, Philadelphia (1977) p. 225.Google Scholar
  48. 48.
    B. Stoliar and D.J. Albert, SCH 13521 in the Treatment of Advanced Carcinoma of the Prostate, J. Urol. 111:803 (1974).PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1983

Authors and Affiliations

  • J. Altwein
    • 1
  1. 1.Bundeswehrkrankenhaus UlmUlmWest Germany

Personalised recommendations